Harvard Business Review

JUNE 29, 2015

And a recent working paper out of the Dusseldorf Institute for Competition Economics ( DICE ), a think tank of sorts, focuses on the latter by exploring whether leveraged buyouts (LBOs) make firms more innovative. PE investors don’t typically invest in firms known for innovation.

LBO 8

LBO Innovation Sample Short-term 8

Harvard Business Review

APRIL 2, 2018

There is an abundance of high-quality comparative effectiveness data for pharmaceuticals, largely because of the drug approval process, but there’s less data on the value of other expensive investments into health, such as doctor visits and hospitalizations. (For

Health Care 8

Health Care Insurance Pharmaceuticals Incentives 8

Harvard Business Review

JUNE 9, 2017

How the most innovative providers are creating value. Equally troublesome, almost all policies focus exclusively on payments and finances but ignore the powerful influence of careerism and other non-financial motives that may compromise objectivity far more than financial incentives. Insight Center. The Leading Edge of Health Care.

Conflict of Interest 10

Conflict of Interest Pharmaceuticals Policies Industry 10

Harvard Business Review

JULY 4, 2017

Apple is so great at connectivity, aesthetics, and entertainment that any vehicle they develop will incorporate these as table stakes. One way to appeal to this demographic (and to the parents who often finance young drivers’ transportation) is to focus on safety. How about a man cave on wheels? Or a kitchen?

Transportation 10

Transportation Sports Pharmaceuticals Health Care 10

Harvard Business Review

OCTOBER 13, 2011

The pharmaceutical industry also creates products with complex interactions and potentially dangerous side effects. Yet unlike in finance, where distributing risk across institutions is the goal, in drug development the focus is on isolating risk. Here, the protocols from other industries can provide some insight.

Banking 10

Banking Pharmaceuticals Microfinance Risk Management 10

Harvard Business Review

JUNE 8, 2015

Pharmaceutical companies, buffeted by regulatory changes, new drug technologies that alter entry barriers and competition, price pressures, and an estimated 300,000 job cuts since 2000, seem to fit the popular narrative of large organizations unable to deal with disruptive forces. It’s not just products.

Health Care 8

Health Care Venture Capitalist Strategic Fit Pharmaceuticals 8

Harvard Business Review

MAY 26, 2014

Four dynamics are driving this new era of health care innovation: Finally, there is a financial incentive to innovate. Top-tier thinkers from data science, business, finance, and the digital world are coming together to find new solutions. Entrepreneurship Health Innovation'

Health Care 8

Health Care Venture Funding Entrepreneur Pharmaceuticals 8

Harvard Business Review

APRIL 19, 2016

Imagine the changes afoot in the pharmaceutical, medical device, automotive, and consumer electronics industries. Innovation, customization, speed, and location are also among the opportunities it offers. Moving forward, consider the following questions for strategic development: Opportunity analysis.

Supply Chain 8

Supply Chain Execution Analysis Technology 8

Harvard Business Review

OCTOBER 25, 2018

The superstars tend to be more involved in global flows of trade and finance, more digitally mature, and they dominate the lists of the most valued companies, the most valued brands, the most desirable places to work, and the most innovative companies. The churn rate of superstar cities is half that of superstar firms.

Industry 13

Industry Company GDP Bottom-up 13

Harvard Business Review

SEPTEMBER 5, 2016

The UK’s Department for International Development uses “results-based” aid to improve the educational outcomes of young girls in Africa and Asia. Cigna is the first insurance company to get pharmaceutical companies to agree to value pricing based on results for certain cholesterol-lowering drugs. ” Health care.

Incentives 8

Incentives Health Care Education Insurance 8

Harvard Business Review

FEBRUARY 4, 2013

Our research with members of the global C-suite, and with leading sustainability and innovation experts, has identified seven vectors of breakthrough change. Levi Strauss, intriguingly, has used biomimetic techniques in developing new production techniques for jeans. Breakthrough Finance. Breakthrough Science.

EPS 8

EPS Innovation CEO Pharmaceuticals 8

Harvard Business Review

SEPTEMBER 4, 2015

Innovation is widely regarded as important to long-term business performance. However, CEOs often don’t have the career background and education that would equip them to personally lead the process of new product development. The data captured a 20-year period, from 1995 to 2014. Overall, it is a messy picture.

CEO 8

CEO Innovation Pharmaceuticals Merchandising 8

Harvard Business Review

NOVEMBER 20, 2015

One result is that they keep their cards close to their chests about what they are looking for (at first), while expecting you to reveal everything – your finances, pricing, ownership, human resources, production processes, quality assurance, customer service procedures, KPIs, and existing customers.

Supply Chain 8

Supply Chain Collins Golden Handcuff Pharmaceuticals 8

Harvard Business Review

OCTOBER 24, 2014

In addressing the billion-dollar adherence problem, Vitality (since acquired by NANTHEALTH ) considered the interests of the players in the diverse ecosystem, including pharmaceutical companies, retail pharmacies, and health care providers. HR has the job of developing the human capabilities needed to capture the IoT opportunity.

Productivity 8

Productivity Products Company Engineering 8

Mills Scofield

NOVEMBER 11, 2014

This is taken from The Intercollegiate Finance Journal (IFJ) is an undergraduate student-run journal about how current finance, economics, business and technology issues affect students'' lives. Instead, the corporate tax code needs to be streamlined and the tax rate lowered to be on par with that of other developed nations.

Finance 131

Finance Incentives Education Pharmaceuticals 131

Harvard Business Review

JUNE 20, 2017

While consumer spending has proven resilient, with same-store retail sales rising 6% YOY in April , most multinational corporations are developing contingency plans to mitigate risks to their businesses and reassessing the country’s role in their global market portfolio and supply chains. Renegotiating NAFTA.

Supply Chain 9

Supply Chain Depreciation Uncertainty Marketing 9